PER-098-10已完成未知
A PHASE III, MULTICENTRE, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 50（—）
入选标准
- •Ability to provide written informed consent and to follow the protocol evaluation program.
- •PPMS diagnosis according to McDonald´s revised criteria (2005)
- •Age 18-55 years, inclusive
- •EDSS in the selection of 3.0 to 6.5 points
- •Rating of> 2.0 on the Functional Systems (ES) scale for the pyramid system due to the lower limb results.
- •urination of the disease from the onset of MS symptoms
- •Documented history or presence in the selection of at least one of the following laboratory results in a CSF sample [source documentation of laboratory results and method must be verified)]
- •For sexually active patients of both sexes with reproductive potential, use of reliable means of contraception as described below as a minimum (compliance with local requirements is necessary if they are more stringent)
排除标准
- •History of recurrent remitting multiple sclerosis, secondary progressive, or progressive recurrent multiple sclerosis in the selection.
- •Inability to complete a MRL (contraindications for MRI include but are not restricted to weight> 140 kg, pacemakers, cochlear implants, intracranial vascular clips, surgery within 6 weeks prior to study entry, coronary stent implant within 8 weeks prior to the time of the planned MRI, etc.). Patients with gadolinium contraindication may be included in the study, but may not receive gadolinium contrast media during their MRI studies.
- •Contraindications to or intolerance to oral corticosteroids or IV, including methylprednisolone administered IV, according to the country´s technical data sheet
- •Known presence of other neurological disorders
- •Pregnancy or breastfeeding;
- •Lack of peripheral venous access;
- •History of severe allergic or anaphylactic reactions to murine or humanized monoclonal antibodies; 8. Significant uncontrolled disease, such as cardiovascular disease (including cardiac arrhythmia), pulmonary (including obstructive pulmonary disease), kidney, liver, endocrine or gastrointestinal disease, or any other significant disease that could prevent the patient from participating in the study.
- •Congestive heart failure (NYHA functional severity class III or IV);
- •Known active bacterial, viral, fungal, mycobacterial or other infection [including tuberculosis [TB] or atypical mycobacterial disease (but excluding fungal infection of nail beds) or any major episode of infection that requires hospitalization or treatment with antibiotics i.v. within 4 weeks prior to the baseline visit (visit 2) or oral antibiotics during the 2 weeks prior to the baseline visit (visit 2);
- •Istoria or known presence of chronic or recurrent infection (for example, HIV, syphilis, tuberculosis);
- •History of recurrent aspiration pneumonia that requires antibiotic treatment.
- •History of cancer, including solid tumors and hematologic malignancies (except basal cell and spinocellular carcinoma in situ of the skin, and carcinoma in situ of the cervix that have been removed and resolved, with clean margins documented in the pathology);
- •Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study;
- •History of alcohol or other drug abuse within 24 weeks prior to randomization;
- •History or active presence of primary or secondary immunodeficiency;
- •History or laboratory evidence of coagulation disorders.
- •Treatment with any investigational drug within 24 weeks prior to selection (visit 1) or five half-lives of the investigational medication (whichever is longer); or treatment with any experimental procedure for MS (for example, treatment for chronic cerebrospinal venous insufficiency).
研究者
相似试验
撤回
3 期
A PHASE III, MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF GANTENERUMAB IN PARTICIPANTS AT RISK FOR OR AT THE EARLIEST STAGES OF ALZHEIMER*S DISEASEdementiaeurologischziekte van AlzheimerAlzheimer's diseaseNL-OMON50277Roche Nederland B.V.60
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer’s DiseaseAlzheimer's Disease (AD)MedDRA version: 20.0Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)System Organ Class: 100000004852EUCTR2021-001184-25-ESRoche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd1,200
进行中（未招募）
1 期
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer’s DiseaseAlzheimer's Disease (AD)MedDRA version: 20.0Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)System Organ Class: 100000004852EUCTR2021-001184-25-SEF. Hoffmann-La Roche Ltd1,200
进行中（未招募）
不适用
A PHASE III, MULTICENTER, RANDOMIZED,PLACEBO-CONTROLLED TRIAL EVALUATINGTHE EFFICACY AND SAFETY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPYREGIMENS IN SUBJECTS WITH PREVIOUSLY TREATED METASTATIC BREAST CANCEREstudio en fase III, multicéntrico, aleatorizado, controlado con placebo para evaluar la eficacia y la seguridad de Bevacizumab en combinación con regímenes de quimioterapia en pacientes con cáncer de mama metastático que hayan sido previamente tratados. - Ribbon-2Previously Treated Metastatic Breast CancerCancer de mama metastásico previamente tratadoMedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-006507-36-ESGenentech Inc.386
进行中（未招募）
不适用
A PHASE III, MULTICENTER, RANDOMIZED,PLACEBO-CONTROLLED TRIAL EVALUATINGTHE EFFICACY AND SAFETY OF BEVACIZUMABIN COMBINATION WITH CHEMOTHERAPYREGIMENS IN SUBJECTS WITH PREVIOUSLYTREATED METASTATIC BREAST CANCER - Ribbon-2Previously Treated Metastatic Breast CancerMedDRA version: 8.1Level: LLTClassification code 10027475Term: Metastatic breast cancerEUCTR2006-006507-36-LVGenentech Inc.386